Company: CERO
Filing Date: 2025-11-17
Form Type: NT 10-Q
Source: 0001213900-25-111295
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: NT 10-Q
Chunk 4
---
’s
internal control over financial reporting, the completion of the preparation of the Company’s financial statements and the subsequent
occurrence or identification of events prior to the filing of the consolidated condensed financial statements for the quarter ended September
30, 2025 in its Quarterly Report. In addition, any such statements regarding the Company’s financial performance are not necessarily
indicative of the Company’s financial performance that may be expected to occur for the quarter ended September 30, 2025, or for
any future fiscal period.

Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein. This list
is not exhaustive of the factors that may affect any of the Company’s forward-looking statements. Forward-looking statements are
statements about the future and are inherently uncertain, and actual achievements of the Company or other future events or conditions
may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties, and other factors,
including without limitation those discussed under Part I, Item 1A. “Risk Factors” contained in the Company’s most recent
Annual Report on Form 10-K, and Part II, Item 1A. “Risk Factors” contained in the Company’s subsequent Quarterly Reports
on Form 10-Q, as well as any amendments thereto.

The Company’s forward-looking statements
contained in this document are based on the beliefs, expectations, and opinions of management as of the date of this document. The Company
does not assume any obligation to update forward-looking statements if circumstances or management’s beliefs, expectations, or opinions
should change, except as required by law. For the reasons set forth above, investors should not attribute undue certainty to, or place
undue reliance on, forward-looking statements.

<div align='center'>3

CERo Therapeutics Holdings, Inc.

(Name of Registrant as Specified in Charter)</div>

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.

| Date: November 17, 2025 | By: | /s/ Andrew Kucharchuk |                         |
|:------------------------|:----|:----------------------|:------------------------|
|                         |     | Name:                 | Andrew Kucharchuk       |
|                         |     | Title:                | Chief Financial Officer |

<div align='center'>4</div>